Sponsor Dossier
Merck Sharp & Dohme
Sponsor Dossier for Merck Sharp & Dohme. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: BELSOMRA
- Brand: CAPVAXIVE
- Brand: DIFICID
- Brand: ENFLONSIA
- Brand: GARDASIL
- Brand: H-B-VAX II
- Brand: INVANZ
- Brand: ISENTRESS
- Device (sponsor): Prefilled syringe/needle
About
Merck Sharp & Dohme is an Australian Private Company with ABN 14000173508, registered in New South Wales. The entity is active and registered for GST from 1 July 2000.
Portfolio
Merck Sharp & Dohme has 33 brands on the ARTG, of which 28 are indexable. The portfolio includes 28 brands with Product Information on file, 7 brands with at least one PBS-listed item, 12 brands with PBAC outcome records, and 9 brands with AusPAR records. Notable brands in the portfolio include Belsomra, Capvaxive, Dificid, Enflonsia, Gardasil, H-B-Vax II, Invanz, Isentress, Janumet, Januvia, Keytruda and Lagevrio.
Therapeutic focus
The portfolio is distributed across seven therapeutic areas as follows: — Infectious Disease: 17 brands — Oncology: 6 brands — Endocrinology: 4 brands — Immunology: 2 brands — Respiratory: 2 brands — Haematology: 1 brand — Neurology: 1 brand
PBS footprint
Merck Sharp & Dohme has 7 brands with at least one PBS-listed item. The latest PBS schedule date the portfolio touched is 1 May 2026.
Regulatory activity
The most recent PBAC outcome for Merck Sharp & Dohme is dated 1 December 2025, with 12 brands holding PBAC outcome records. The most recent AusPAR is dated 30 January 2025, with 9 brands holding AusPAR records.